Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals.

Tytuł:
COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals.
Autorzy:
Singh A; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; and.
Brandow AM; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; and.; Children's Hospital of Wisconsin, Milwaukee, WI.
Panepinto JA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI; and.; Children's Hospital of Wisconsin, Milwaukee, WI.
Źródło:
Blood advances [Blood Adv] 2021 Apr 13; Vol. 5 (7), pp. 1915-1921.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Washington, DC : American Society of Hematology, [2016]-
MeSH Terms:
Anemia, Sickle Cell*/complications
Sickle Cell Trait*/complications
Black or African American/*statistics & numerical data
COVID-19/*epidemiology
Adolescent ; Adult ; Female ; Humans ; Male ; Middle Aged ; United States/epidemiology ; Young Adult
References:
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. (PMID: 32667669)
Hematol Transfus Cell Ther. 2020 Jul - Sep;42(3):212-214. (PMID: 32646838)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
BMJ. 2020 Mar 26;368:m1198. (PMID: 32217618)
Ann Intern Med. 2018 Nov 6;169(9):619-627. (PMID: 30383109)
Br J Haematol. 2020 Jul;190(2):e57-e58. (PMID: 32369606)
JAMA Intern Med. 2020 Jul 15;:. (PMID: 32667668)
Health Aff (Millwood). 2020 Jul;39(7):1253-1262. (PMID: 32437224)
Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463)
JAMA Neurol. 2018 Jul 1;75(7):802-807. (PMID: 29710269)
Emerg Infect Dis. 2020 Oct;26(10):2473-2476. (PMID: 32639228)
Am J Med. 2009 Jun;122(6):507-12. (PMID: 19393983)
Blood Adv. 2019 May 28;3(10):1574-1580. (PMID: 31101648)
Am J Hematol. 2020 Jul;95(7):876-878. (PMID: 32282956)
J Gen Intern Med. 2020 Apr;35(4):1323-1324. (PMID: 31745854)
N Engl J Med. 2020 Jun 25;382(26):2534-2543. (PMID: 32459916)
Hemoglobin. 2020 Jul;44(4):284-289. (PMID: 32722950)
Am J Hematol. 2020 Aug;95(8):E192-E194. (PMID: 32358817)
Thromb J. 2018 Oct 4;16:27. (PMID: 30305805)
Lancet Haematol. 2020 Sep;7(9):e632-e634. (PMID: 32563282)
Haematologica. 2020 Jun 11;105(11):2691-2693. (PMID: 33131264)
Br J Haematol. 2020 Jun;189(5):851-852. (PMID: 32314798)
JAMA Netw Open. 2021 Jan 4;4(1):e2030435. (PMID: 33399855)
Blood. 2010 Nov 4;116(18):3431-4. (PMID: 20656929)
Pediatrics. 2010 Feb;125(2):234-43. (PMID: 20100764)
Lancet. 2020 Jun 6;395(10239):1763-1770. (PMID: 32442528)
Entry Date(s):
Date Created: 20210401 Date Completed: 20210423 Latest Revision: 20221207
Update Code:
20240104
PubMed Central ID:
PMC8015795
DOI:
10.1182/bloodadvances.2020003741
PMID:
33792626
Czasopismo naukowe
In the United States, COVID-19 has disproportionately affected Black persons. Sickle cell disease (SCD) and sickle cell trait (SCT) are genetic conditions that occur predominantly among Black individuals. It is unknown if individuals with SCD/SCT are at higher risk of severe COVID-19 illness compared with Black individuals who do not have SCD/SCT. The objective of our study was to compare COVID-19 outcomes, including the disease manifestations, hospitalization, and death, among individuals with SCD/SCT vs Black individuals who do not have SCD/SCT. We leveraged electronic health record data from a multisite research network to identify Black patients with COVID-19 who have SCD/SCT and those who do not have SCD/SCT. During the study period of 20 January 2020 to 20 September 2020, there were 312 patients with COVID-19 and SCD and 449 patients with COVID-19 and SCT. There were 45 517 Black persons who were diagnosed with COVID-19 but who did not have SCD/SCT. After 1:1 propensity score matching (based on age, sex, and other preexisting comorbidities), patients with COVID-19 and SCD remained at a higher risk of hospitalization (relative risk [RR], 2.0; 95% CI, 1.5-2.7) and development of pneumonia (RR, 2.4; 95% CI, 1.6-3.4) and pain (RR, 3.4; 95% CI, 2.5-4.8) compared with Black persons without SCD/SCT. The case fatality rates for those with SCD compared with Black persons without SCD/SCT were not significantly different. There also were no significant differences in COVID-19 outcomes between individuals with SCT and Black persons without SCD/SCT within the matched cohorts.
(© 2021 by The American Society of Hematology.)
Erratum in: Blood Adv. 2022 Apr 26;6(8):2535. (PMID: 35446383)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies